A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Two Period Crossover, Single Dose-Finding Study to Assess the Efficacy and Safety of Controlled Release XP19986 in Patients With Gastroesophageal Reflux Disease.

Trial Profile

A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Two Period Crossover, Single Dose-Finding Study to Assess the Efficacy and Safety of Controlled Release XP19986 in Patients With Gastroesophageal Reflux Disease.

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Sep 2016

At a glance

  • Drugs Arbaclofen placarbil (Primary)
  • Indications Gastro-oesophageal reflux
  • Focus Therapeutic Use
  • Sponsors XenoPort
  • Most Recent Events

    • 29 Dec 2009 Primary endpoint 'Gastrointestinal symptoms' has been met.
    • 29 Dec 2009 Results published in The American Journal of Gastroenterology.
    • 09 Dec 2009 New source identified and integrated (ClinicalTrials.gov record no. NCT00838396).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top